Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 6/20 | 0.53 |
| ▸ | NPC1 | O15118 | 4/20 | 0.46 |
| ▸ | HPGD | P15428 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | HPGDS | O60760 | 1/20 | 0.44 |
| ▸ | LDHA | P00338 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16495586 | 0.88 | HPGDS (0.56) | EGLN1NPC1HPGDKMT2ASMN1; SMN2 | |
| SCHEMBL16496456 | 0.85 | HPGDS (0.54) | EGLN1NPC1HPGDHPGDS | |
| SCHEMBL16495886 | 0.84 | EGLN1 (0.49) | EGLN1NPC1HPGDKMT2ASMN1; SMN2 | |
| SCHEMBL16496432 | 0.79 | HPGD (0.51) | EGLN1NPC1HPGDKMT2ASMN1; SMN2 | |
| SCHEMBL16496157 | 0.79 | RAB9A (0.67) | EGLN1NPC1HPGDKMT2ASMN1; SMN2 | |
| SCHEMBL16496718 | 0.77 | MAPT (0.49) | EGLN1NPC1HPGDKMT2ASMN1; SMN2 | |
| SCHEMBL16495956 | 0.75 | HPGD (0.64) | NPC1HPGDKMT2ASMN1; SMN2HPGDS | |
| SCHEMBL16495566 | 0.75 | RAB9A (0.61) | NPC1HPGDKMT2ASMN1; SMN2LMNA | |
| SCHEMBL16495642 | 0.74 | GAA (0.48) | EGLN1NPC1HPGDRAB9A | |
| SCHEMBL16495637 | 0.74 | MAP4K4 (0.46) | EGLN1HPGDSLDHAKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110306597-A1 | Nicotinamide Derivatives | CRAWFORTH JAMES MICHAEL (GB) | 2011-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306597-A1 | Nicotinamide Derivatives | NNT, NAMPT, NQO1 | EGLN1 1302/4885NPC1 236/4885HPGD 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.